View in EDS HTML Full Text PDF Full Text

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study.

Saved in:
Bibliographic Details
Title: Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study.
Authors: Hu, Jiao1,2,3 (AUTHOR), Yan, Luzhe1,2,3 (AUTHOR), Liu, Jinhui1,2,3 (AUTHOR), Chen, Minfeng1,2,3 (AUTHOR), Liu, Peihua1,2,3 (AUTHOR), Deng, Dingshan1,2,3 (AUTHOR), Zhang, Chaobin1,2,3 (AUTHOR), He, Yunbo1,2,3 (AUTHOR), Fan, Benyi1,2,3 (AUTHOR), Li, Huihuang1,2,3 (AUTHOR), Gong, Guanghui4 (AUTHOR), Xiao, Jiatong1,2,3 (AUTHOR), Wang, Ruizhe1,2,3 (AUTHOR), Guan, Xiao1,2,3 (AUTHOR), Tong, Shiyu1,2,3 (AUTHOR), Li, Yangle1,2,3 (AUTHOR), Li, Nannan5 (AUTHOR), Tang, Zhiwang5 (AUTHOR), Zhang, Teng6 (AUTHOR), Li, Hao6 (AUTHOR)
Source: iMeta. Jun2025, Vol. 4 Issue 3, p1-9. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:27705986
DOI:10.1002/imt2.70033